1 Cystic fibrosis risk variants confer protection against inflammatory bowel disease

2

3 Authors

- 4 Mingrui Yu^{1,2}, Qian Zhang³, Kai Yuan^{1,2}, Aleksejs Sazonovs³, Christine Stevens^{1,2,4}, Laura
- 5 Fachal³, the International Inflammatory Bowel Disease Genetics Consortium, Carl A.
- 6 Anderson^{3,*}, Mark J. Daly^{1,2,4,*}, Hailiang Huang^{1,2,*}
- 7
- ¹Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA
- 9 ²Stanley Center for Psychiatric Research, the Broad Institute of MIT and Harvard, Cambridge,
- 10 MA, USA
- ³Genomics of Inflammation and Immunity Group, Human Genetics Programme, Wellcome
 Sanger Institute, Wellcome Genome Campus, Hinxton, UK.
- 13 ⁴Program in Medical and Population Genetics, The Broad Institute of MIT and Harvard,
- 14 Cambridge, MA, USA
- 15
- 16 *These authors jointly supervised this work. Emails: <u>ca3@sanger.ac.uk</u>,
- 17 <u>mjdaly@broadinstitute.org</u>, <u>hhuang@broadinstitute.org</u>
- 18

19 Abstract

20 Genetic mutations that yield defective cystic fibrosis transmembrane regulator (CFTR) protein

- 21 cause cystic fibrosis, a life-limiting autosomal recessive Mendelian disorder. A protective role of
- 22 *CFTR* loss-of-function mutations in inflammatory bowel disease (IBD) has been suggested, but
- 23 its evidence has been inconclusive and contradictory. Here, leveraging the largest IBD exome
- sequencing dataset to date, comprising 38,558 cases and 66,945 controls in the discovery stage,
- and 35,797 cases and 179,942 controls in the replication stage, we established a protective role of
- CF-risk variants against IBD based on evidence from the association test of *CFTR* delF508 (p-value=8.96E-11) and the gene-based burden test of CF-risk variants (p-value=3.9E-07).
- 28 Furthermore, we assessed variant prioritization methods, including AlphaMissense, using
- 29 clinically annotated CF-risk variants as the gold standard. Our findings highlight the critical and
- 30 unmet need for effective variant prioritization in gene-based burden tests.
- 31

32 Genetic mutations that yield defective cystic fibrosis transmembrane regulator (CFTR) protein are known to cause cystic fibrosis $(CF)^1$, one of the most common life-threatening autosomal 33 recessive genetic disorders among individuals of European ancestry. CFTR is a transmembrane 34 chloride ion channel gene highly expressed in epithelial cells². Defective CFTR protein located 35 in the epithelial cell membrane results in defective chloride ion transport³, which leads to water 36 37 depletion at the cell surface and thick mucus buildup in organs such as the lung, pancreas, sweat 38 gland, and gut. Cellular signaling pathways through which the innate immune system elicits proper immune responses are dysregulated in CF⁴⁻¹⁰, leading to hyperinflammation. However, it 39 is unclear whether CFTR mutations are intrinsically pro-inflammatory or whether the heightened 40 41 inflammation observed in CF results from a heightened response to exacerbated pathogen 42 exposure^{11–14}.

43

54

44 Inflammatory bowel disease (IBD) is a disorder with chronic inflammation in the gastrointestinal 45 tract. Although earlier research suggested that loss-of-function variants in the CFTR gene may lead to a lower prevalence of intestinal inflammation¹⁵ and potentially protect against IBD, 46 evidence has been inconsistent with studies showing conflicting results - some linking these 47 variants to increased risk, others suggesting protection, and some finding no effect at all¹⁶⁻¹⁹. 48 Here, leveraging the largest IBD exome sequencing dataset to date, comprising 38,558 cases and 49 66,945 controls in the discovery stage, and 35,797 cases and 179,942 controls in the replication 50 51 stage, we provide conclusive evidence that CF-risk variants in CFTR confer a protective effect 52 against IBD, and demonstrated the importance of variant prioritization in gene-based burden 53 tests.

55 **RESULTS**

Study subjects. Broad Institute (Discovery): Exome sequencing was performed at the Broad 56 57 Institute. Study subjects were recruited from different centers and shared with the International 58 Inflammatory Bowel Disease Genetics Consortium (IIBDGC) for 38,558 IBD cases and 66,945 controls after quality control analysis (Table 1). Among the cases, 21,478 have Crohn's disease 59 (CD), 14,353 have ulcerative colitis (UC), and 2,727 have IBD unclassified (IBD-U). Sanger 60 Institute (Replication): Additional exome and whole genome sequencing were undertaken at the 61 62 Sanger Institute. Whole exome sequencing was performed on 10,722 CD, 13,147 UC, and 6,211 IBD-U, which were matched with whole exome sequencing data obtained from 168,100 controls 63 from the UK Biobank. Extensive quality control was undertaken to harmonize the case and 64 control exome sequencing data (Methods). Whole genome sequencing was performed on another 65 independent sample of 5,717 CD and 11,842 controls. Details on sequencing and data quality-66 67 control protocols are described in Methods.

1	Center	Stage	Method	Controls	CD	UC	IBD-U
	Broad	Discovery	WES	66,945	21,478	14,353	2,727

Sanger	Replication	WES	168,100	10,722	13,147	6,211
		WGS	11,842	5,717	0	0

Table 1. Study sample sizes. The number of individuals of European ancestry included in the association analyses,
 post-quality control (Methods). WES: whole-exome sequencing; WGS: whole-genome sequencing.

71

72 **CF-causing variant deltaF508 confers a protective effect against IBD.** The *CFTR* deltaF508 73 is an in-frame deletion variant commonly observed in the European population, with a minor 74 allele frequency (MAF) of 1.5% in non-Finnish Europeans (chr7:117559590:ATCT:A in 75 Genome Reference Consortium Human Build 38 [GRCh38]). Homozygous deltaF508 has full penetrance for CF and is the most common CF-causing variant. Single variant association 76 77 analysis in the Broad discovery dataset using a logistic mixed model (Methods) found that deltaF508 had a significant protective effect against both CD (p-value=1.53E-7, OR=0.73 [0.65-78 79 0.82, 95% CI) and UC (p-value=3.35E-4, OR=0.79 [0.69-0.90, 95% CI], Table 2). This association also reached nominal significance for CD in the Sanger WES and WGS datasets (p-80 value=3.52E-02 and 8.32E-3. Table 2) with both protective effects. After meta-analysis, the 81 82 protective effect of deltaF508 on CD reached genome-wide significance (p-value=5.5E-9). There are no known IBD-associated variants (defined as variants with posterior inclusion probability > 83 5% from fine-mapping²⁰ or reported in the published sequencing and genome-wide association 84 studies^{21–23}) within 1 million base pairs of deltaF508, therefore it is highly unlikely that the 85 deltaF508 association tags a known IBD genetic association. 86 87

Study	Subtype	MAF (case)	MAF(control)	p-value	ВЕТА	SE	OR (95% CI)
Broad WES	CD	0.0097	0.0136	1.53E-07	-0.305	0.059	0.65 - 0.82
(Discovery)	UC	0.0096	0.0136	3.35E-04	-0.234	0.066	0.69 - 0.90
	IBD	0.0097	0.0136	8.50E-10	-0.289	0.047	0.68 - 0.82
Sanger WES	CD	0.0135	0.0161	3.52E-02	-0.136	0.064	0.77 - 0.99
(Replication)	UC	0.0141	0.0161	2.04E-01	-0.073	0.058	0.83 - 1.04
	IBD	0.0137	0.0161	1.47E-02	-0.108	0.044	0.82 - 0.98
Sanger WGS (Replication)	CD/IBD	0.0114	0.0157	8.32E-03	-0.310	0.117	0.58 - 0.92
Meta-analysis	CD	-	-	5.49E-09	-0.238	0.041	0.73 - 0.85
	UC	-	-	9.95E-04	-0.143	0.043	0.79 - 0.94
	IBD	-	-	8.96E-11	-0.201	0.031	0.77 - 0.87

Table 2. Association between deltaF508 and CD, UC, and IBD. MAF: minor allele frequency; BETA, SE: effect

89 size, and standard error from a logistic mixed model; OR (95% CI): 95% confidence interval of odds ratio (OR).

91 To limit the potential for confounded CF status to bias the allele frequency estimates in our cases 92 and controls, we repeated the association analysis after excluding 4 cases and 47 controls who 93 were homozygous carriers of deltaF508 in the discovery and replication cohorts combined, as 94 well as 37 cases and 170 controls deemed potential compound heterozygous carriers 95 (Supplementary Tables 1), defined as individuals with two or more variants annotated as "CFcausing" or "Varying clinical consequence" in the Clinical and Functional Translation of CFTR²⁴ 96 97 (CFTR2) database. We found that the associations between CFTR deltaF508 and CD/UC/IBD remain significant (Supplementary Tables 2), supporting the conclusion that deltaF508 plays a 98 protective role in IBD. 99

100

101 *CFTR* mutations confer protection against IBD in gene-based burden tests.

102 The CFTR2 database contains a comprehensive list of CFTR variants known to impair CFTR 103 protein function and cause CF. The Broad discovery dataset captured 1036 CFTR variants 104 (Supplementary Tables 3). 170 of the 1035 CFTR variants were annotated in CFTR2 as "CF-105 causing" (109), "Varying clinical consequence" (33), "Non CF-causing" (19), or "Unknown significance" (9). The remaining 865 variants did not have an annotation in CFTR2. We defined 106 "CF-risk" variants (142) as variants annotated as "CF-causing" or "Varying clinical 107 consequences" in the CFTR2 database, and "Non-CF-risk" variants (893) as variants annotated 108 109 as "Non CF-causing", "Variants of unknown significance" in CFTR2, or without annotation in 110 CFTR2.

111

112 While no variants other than deltaF508 reached even nominal levels of significance (p-


value<0.01) in our single variant tests, CF-risk variants are predominantly protective against IBD

114 (p-value=0.002, binomial test using variants with minor allele count ≥ 10 in the Broad dataset,

115 Figure 1a). Conversely, non-CF-risk variants were not enriched with protective effects (p-

value=0.35, binomial test using variants with minor allele count ≥ 10 in the Broad dataset, Figure 117 (1b)

117 lb).



118

Figure 1: Single-variant association tests for CFTR variants with minor allele count (MAC) ≥ 10 in the Broad
 dataset. a) Distribution of p-values (from logistic mixed model) and MAF for 37 CF-risk variants. b) Distribution
 of p-values (from logistic mixed model) and MAF for 96 non-CF-risk variants.

122

123 Based on these observations, we hypothesize that variants impairing CFTR function are protective against IBD. To test this hypothesis, we did an unweighted burden test of CFTR using 124 125 the 141 CF-risk variants (deltaF508 not included as itself confers a significant protective effect). 126 We found these variants in aggregation have a significant protective effect on IBD in the Broad 127 dataset (P=4.3E-06, beta=-0.21, se=0.047) (Table 3), which was replicated in the Sanger WES dataset at nominal significance (P=0.037, beta=-0.11, se=0.052) and in the Sanger WGS dataset 128 129 for the direction and effect size with CD (p-value=0.073, beta=-0.15, se=0.088). The Sanger 130 WGS is much smaller in the sample size thus, the lack of significance is likely due to its limited power. Combining all three datasets using the fixed-effect meta-analysis, we found CF-risk 131 variants in CFTR collectively confer a protective effect of -0.164 (OR=0.85) with p-value=3.9E-132 133 7. This association was significant when tested for CD and UC separately (meta-analysis for CD: 134 beta=-0.13, se=0.039, p-value=8.8E-04; UC: beta=-0.23, se=0.049, p-value=3.6E-06) 135 (Supplementary Table 4). On the contrary, we did not observe a significant association with IBD using the non-synonymous variants that were classified as non-CF-risk in CFTR (p-value=0.37 136 137 and 0.56, Table 3). Taken together, these results confirm our hypothesis that rare variants that impair CFTR function reduce the risk of IBD. 138

		Molecular	Clinical		# of				
Study	Subtype	annotation	annotation	MAF	Variants	CAF	BETA	SE	p-value

Broad WES	IBD	-	CF-risk	-	141	0.012	-0.21	0.047	4.3E-06
Sanger WES	IBD	-	CF-risk	-	128	0.011	-0.11	0.052	0.037
Sanger WGS	CD/IBD	-	CF-risk	-	56	0.023	-0.16	0.088	0.073
Meta-analysis		-	CF-risk	-	-	-	-0.164	0.032	3.9E-07
Broad WES	IBD	Non-synonymous	non-CF-risk	< 0.001	697	0.017	-0.03	0.038	0.37
Sanger WES	IBD	Non-synonymous	non-CF-risk	< 0.001	844	0.021	-0.063	0.037	0.090
Sanger WGS	CD/IBD	Non-synonymous	non-CF-risk	< 0.001	180	0.020	-0.058	0.097	0.55

140

Table 3. CFTR burden test results using clinical variant annotations. CAF: composite allele frequency, defined 141 as the frequency of observing carriers of at least one variant of interest in the study. We applied an MAF upper 142 bound to burden tests using non-CF-risk variants so that the CAFs are similar to those of CF-risk variants.

143

144 Variant annotation plays a critical role in burden tests

145 The power of rare variant burden tests increases with the composite allele frequency and the 146 proportion of causal to non-causal rare variants included in the analysis. Therefore, identifying a 147 variant set that maximizes the inclusion of causal variants while minimizing non-causal variants 148 is crucial to enhancing the power of the burden test. A common approach employed by the 149 burden test is to use predicted loss of function variants or rare (MAF < 0.1%) non-synonymous variants. In both scenarios, we found much weaker evidence of association (p-value=1.01E-03 150 151 and 0.042, respectively, Table 3) compared to the burden test using CF-risk variants. This 152 demonstrates that clinical variant annotations from the CFTR2 database outperform naive 153 molecular consequence annotations in detecting the impact of rare *CFTR* variants on IBD risk.

154

Molecular annotation	Number of Variants	CAF	BETA	SE	p-value
Predicted loss-of-function	93	0.003	-0.18	0.093	0.042
Non-synonymous	782	0.023	-0.10	0.032	1.01E-03

155 Table 4. CFTR burden test using molecular annotations. Definitions of "predicted loss-of-function" and "non-156 synonymous" variants are described in Methods. We restricted the tests to variants with MAF<0.1%.

157

158 Unfortunately, very few genes are as thoroughly studied and clinically annotated as CFTR. Most 159 human genes lack accurate variant effect annotation. In silico variant pathogenicity predictions can thus play an important role in systematically annotating variants to enhance the power of rare 160 variant burden tests. Recently, Alpha Missense (AM)²⁵, a machine learning model trained on 161 162 protein structure prediction and evolutionary constraint information for predicting missense variant pathogenicity, has been shown to have more accurate missense pathogenicity predictions 163 as evidenced by better correlations with functional assays than previous prediction models²⁶. 164 Thus, we evaluated the utility of AM for prioritizing CFTR missense variants for inclusion in 165 166 burden tests, using the CFTR2 database as the benchmark.

167

168 We annotated 698 CFTR missense variants available in the Broad WES dataset, among which 74 169 are CF-risk variants according to the CFTR2 database (Methods). We observed that most CF-risk

170 variants were predicted as "likely pathogenic" (AM score>0.56) (Figure 2a), and variants with 171 high AM scores (>0.8) had stronger protective effects against IBD (Figure 2b). However, 73% of 172 predicted "likely pathogenic" variants were non-CF-risk in CFTR2. This finding is concordant with those from previous benchmarking studies that showed AM, as well as other pathogenicity 173 prediction models, tend to overcall pathogenic variants^{26,27}. The power to detect association via a 174 variant burden test could therefore be heavily influenced by the AM score threshold used to 175 define the set of variants included in the test. To investigate this, we performed burden tests by 176 selecting CFTR missense variants (restricted to MAF < 0.1%) with AM score threshold ranging 177 from 0 to 1 in increments of 0.01. 178

179

188

180 Our analysis showed that a higher AM score threshold does not always improve the statistical power of the burden test. Statistical power is sensitive to both the effect size (increases with the 181 AM score threshold, Figure 2b) and the composite allele frequency (CAF, decreases with the 182 183 AM score threshold, Figure 2c). Specifically, within the score range of 0.56 to 1, the burden test significance decreased with more stringent AM score cutoffs due to a reduction in CAF, despite 184 a stronger effect size (Figure 2d). To effectively incorporate pathogenicity scores in burden tests, 185 such as AM, further improvements on in silico variant annotations are needed to match the 186 187 accuracy of clinical annotations (Discussion).




Figure 2: Prioritizing *CFTR* variants in burden tests using AlphaMissense. a) AM scores for CF-risk variants and non-CF-risk variants. b) Relative risk for missense variants with AM score above the AM threshold (x-axis).
Relative risk was calculated as CAF in cases / CAF in controls. c) CAFs for missense variants with scores above the AM threshold (x-axis). d) Burden test significance using missense variants with AM scores above the threshold (x-axis). The result using the AM "likely pathogenic" threshold (0.56) is marked with red. We restricted the tests to variants with MAF<0.1%.

195

196 Discussion

Leveraging a large-scale IBD exome sequencing dataset, we showed at single-variant and genebased levels that CF-risk variants in the *CFTR* gene confer a protective effect against IBD. The
gut epithelial barrier plays a fundamental role in maintaining intestinal homeostasis and

protecting against IBD²⁸. Given CFTR mutations are associated with mucus buildup on the 200 201 epithelial cell surface, it is possible that heterozygous CFTR mutations alter the intestinal mucosa 202 which provides an enhancing effect on the gut epithelial barrier. Using a CF mouse model, Gabriel et al^{29} showed that heterozygote carriers of pathogenic CFTR variants are resistant to 203 204 cholera toxin. This resistance is due to reduced intestinal fluid and chloride ion secretion in 205 response to the toxin. In addition, it has been demonstrated that CFTR can serve as an epithelial 206 receptor for S. Typhi transluminal migration and that heterozygous deltaF508 mice translocated significantly fewer S. Typhi into the gastrointestinal submucosa than wild-type CFTR mice³⁰. 207 208 Therefore, it is also plausible that the protective effect of CFTR in IBD may stem from similar interactions with vet unidentified bacteria¹⁹. Our finding suggests a previously under-appreciated 209 role of CF-risk mutations in human health and disease. Follow-up experimental studies are 210 211 warranted to investigate the exact cellular pathways CF-risk mutations disrupt to exert such a 212 protective effect. This may provide insights for an effective therapeutic intervention for IBD.

213

214 The ascertainment bias in CF patients can potentially confound this study. The Broad study 215 ascertained control subjects from hospitals, while the Sanger study mostly ascertained controls 216 from the community via UK Biobank. Therefore, an over-representation of CF patients in the 217 Broad study can potentially create a spurious association between CF-risk variants and IBD. We 218 controlled for this confounding factor by removing all predicted CF patients based on genetic data. While this approach is an approximation and does not guarantee the removal of all CF 219 220 patients, the remaining number of CF patients is very small and should not affect the validity of our conclusion. 221

222

Burden tests are sensitive to the quality of variant annotations. While the clinical evidence-based *CFTR* variant annotations established the protective effect of CF-risk variants on IBD, simply including all predicted loss-of-function or missense variants in the burden test failed to reach exome-wide statistical significance. We evaluated AM, the best-in-class *in-silico* variant pathogenicity predictor, and found that its effectiveness in variant prioritization for burden tests is hampered by insufficient accuracy. Further improvement in pathogenicity prediction models for missense variants is needed. Furthermore, a higher score threshold for selecting variants for

burden tests does not guarantee improvement in statistical power as it may sacrifice sensitivityfor specificity, both of which are needed for a powerful burden test.

231 1

While this study focuses on the effect of *CFTR* mutations on IBD, the exome-wide analysis, incorporating additional samples sequenced at Sanger Institute, is underway. In the very near future, we expect to report a comprehensive list of IBD-associated genes through large-scale exome sequencing analysis.

237

238 ACKNOWLEDGMENTS

239 We thank all of the principal investigators, local staff from individual cohorts, and all of the 240 patients who kindly donated samples used in the study for making possible this global 241 collaboration and resource to advance IBD genetics research. This research was funded in whole, 242 or in part, by the US National Institutes of Health grants no. U54HG003067 and no. 243 5UM1HG008895, the Wellcome Trust grants no. [206194] and no. [108413/A/15/D], and The 244 Leona M. & Harry B. Helmsley Charitable Trust grant no. 2015PG-IBD001. We thank the Broad Institute Genomics Platform for genomic data generation efforts and the Stanley Center for 245 246 Psychiatric Research at the Broad Institute for supporting control sample aggregation. We thank 247 the Sanger Institute Scientific Operations teams and Human Genetics Informatics team for 248 sample handling and data generation. This research was supported by the NIHR IBD 249 BioResource and NIHR Biomedical Research Centres in Cambridge, Oxford, Imperial, UCH and 250 Newcastle. The views expressed are those of the authors and not necessarily those of the NIHR 251 or the Department of Health and Social Care. The NIHR IBD BioResource acknowledges co-252 funding by Crohn's Colitis UK and The Leona M. and Harry B. Helmsley Charitable Trust. H.H. acknowledges support from NIDDK grant no. R01DK129364 and the Stanley Center for 253 254 Psychiatric Research. Individual studies contributing to this project acknowledge support from 255 NIH grants no. DK062431, no. DK062432, no. DK087694, no. K23DK117054, no. 256 R01DK111843, no. P01DK094779, no. R01HG010140, no. 5U01HG009080 and no. DK062420, 257 and NIDDK grants no. P01DK046763, no. U01DK062413, DK 043351 and no. R01DK104844. 258

259 AUTHOR CONTRIBUTIONS

H.H., C.A.A. and M.J.D. designed and supervised the study. C.R.S., L.F., H.H., C.A.A. and
M.J.D. were responsible for project management. M.Y., Q.Z., K.Y., and A.S. performed data
analysis. M.Y. and H.H. wrote the manuscript. All authors have reviewed and approved the
manuscript.

264

265 COMPETING INTERESTS

M.J.D. is a founder of Maze Therapeutics. C.A.A. has received consultancy fees from Genomics
 plc and BridgeBio Inc. and lecture fees from GSK. The remaining authors declare no competing
 interests.

269 METHODS

270 Ethics. All relevant ethical guidelines have been followed, and any necessary institutional 271 review board (IRB) and/or ethics committee approvals have been obtained. The Broad Institute 272 component of this study was approved under Study Protocol 2013P002634 (the Broad Institute 273 Study of Inflammatory Bowel Disease Genetics), and undergoes annual continuing review by the 274 Mass General Brigham Human Research Committee IRB of Mass General Brigham (Mass 275 General Brigham IRB). Approval was given on 27 January 2021 for this study. DNA samples 276 sequenced at the Sanger Institute were ascertained under the following ethical approvals: 277 12/EE/0482, 12/YH/0172, 16/YH/0247, 09/H1204/30, 17/EE/0265, 16/WM/0152, 09/H0504/125, 278 15/EE/0286, 11/YH/0020, 09/H0717/4, REC 22/02, 03/5/012, 03/5/012, 2000/4/192, 279 05/01407/274, 05/00502/127, 08/ H0802/147, LREC/2002/6/18, GREC/03/0273 and 280 YREC/P12/0. All informed consent from participants has been obtained, and the appropriate institutional forms have been archived. 281

282

283 Broad Institute data production

284 Sequencing. The sequencing process included sample preparation (Illumina Nextera, Illumina 285 TruSeq, and Kapa Hyperprep), hybrid capture (Illumina Rapid Capture Enrichment - 37 Mb target ["Nextera", Table 1], and Twist Custom Capture - 37 Mb target ["Twist", Table 1]) and 286 287 sequencing (Illumina HiSeq2000, Illumina HiSeq2500, Illumina HiSeq4000, Illumina HiSeqX, Illumina NovaSeq 6000, 76-base pair (bp) and 150-bp paired reads). Sequencing was performed 288 289 at a median depth of 85% targeted bases at >20×. Sequencing reads were mapped by BWA-290 MEM to the hg38 reference using the GATK 'functional equivalence' pipeline. The mapped 291 reads were then marked for duplicates, and base quality scores were recalibrated. They were then 292 converted to CRAMs using Picard 2.16.0-SNAPSHOT and GATK 4.0.11.0. The CRAMs were 293 then further compressed using ref-blocking to generate gVCFs. These CRAMs and gVCFs were 294 then used as inputs for joint calling. To perform joint calling, the single-sample gVCFs were 295 hierarchically merged.

296

297 Quality control. Quality control (QC) analyses were conducted in Hail v.0.2.128 (Supplementary 298 Figure 1). We first split multiallelic sites and coded genotypes with low genotype quality (GQ <299 20) as missing. To exclude variant sites that fall outside of exome capture, we removed variants 300 that are not annotated as frameshift, inframe deletion, inframe insertion, stop lost, stop gained, 301 start lost, splice acceptor, splice donor, splice region, missense or synonymous. Sample-level QC. Samples that satisfy the following conditions were removed: (1) samples with an extremely large 302 303 number of singletons (\geq 500); (2) samples with mean GQ < 30; (3) samples with missingness 304 rates > 10%; (4) samples with outlying heterozygosity (± 5 s.d. away from mean within the 305 population); (5) samples with inconsistent genetically imputed sex and reported sex; and (6) 306 duplicated samples, which were removed by identifying pairs of samples sharing identical 307 genotypes (PI_HAT > 0.95) and keeping the sample with higher mean GQ. Variant-level QC. 308 Variants that satisfy following conditions were removed: (1) variants with missingness rate > 5%;

309 (2) variants with mean read depth (DP) < 10; (3) variants with >10% samples that were 310 heterozygous and with an allelic balance ratio <0.3 or >0.7; and (4) variants that have known 311 quality issues in both gnomAD v2 and v3 dataset (non-empty values in the "filter" column).

312

313 Ancestry assignment. We trained a random forest classifier using 1000 Genomes Project (1KGP) 314 subjects and ten principal components (PC) derived from a set of ~22000 common variants shared between 1KGP and our callset. We projected all our samples onto the PC space generated 315 316 based on the 1KGP subjects and assigned each of our subject to European (CEU, TSI, FIN, GBR, 317 IBS), African and American (YRI, LWK, GWD, MSL, ESN, ASW, ACB, MXL, PUR, CLM, 318 PEL), East Asian (CHB, JPT, CHS, CDX, KHV), and South Asian (GIH, PJL, BEB, STU, ITU). 319 For this study, we kept samples that were classified as European with a prediction probability 320 greater than 80% (Supplementary Figure 2).

321

322 Sanger Institute data production

323 Sequencing. Genome sequencing was performed at the Sanger Institute using the Illumina HiSeqX platform with a combination of PCR and PCR-free library preparation protocols. 324 325 Sequencing was performed at a median depth of 18.6x. Exome sequencing of IBD cases was 326 performed at the Sanger Institute using the Illumina NovaSeq 6000 and the Agilent SureSelect 327 Human All Exon V5 capture set. Controls from the UK Biobank were sequenced separately as a 328 part of the UKBB WES200K release using Illumina NovaSeq and the IDT xGen Exome 329 Research Panel v1.0 capture set (including supplemental probes). 168,100 UKBB participants 330 with EUR ancestry were selected for use as controls, excluding participants with recorded or 331 self-reported CD, UC, unspecified noninfective gastroenteritis or colitis, any other immune-332 mediated disorders, or a history of being prescribed any drugs used to treat IBD. Reads were 333 mapped to hg38 reference using BWA-MEM 0.7.17. Variant calls were performed using 334 DeepVariant and saved as per-sample gVCFs. These gVCFs are aggregated with GLnexus into 335 joint-genotyped, multi-sample project-level VCFs (pVCFs). Variant calling was limited to 336 Agilent extended target regions. Per-region VCF shards were imported into the Hail software and 337 combined. This study considered variants located in intersection regions of Agilent and IDT exome captures + 100bp buffer. 338

339

340 Quality control Exome sequencing: A combination of filters was used to identify low-quality 341 variants and samples. Genotype calls with low genotype quality (GQ < 20) in rare variants (MAF < 0.1%) were set as missing. A variant level QC was then applied by keeping variants that meet 342 343 all the following criteria in both case (Sanger WES) and control (UKBB WES) samples: (1) 344 mean GO > 30; (2) mean read depth (DP) > 10; and (3) call rate > 0.95. Samples satisfying any 345 of the following conditions were removed: (1) low average GO (\leq 30); (2) low call rate (\leq 0.9); 346 (3) disagreement between genetically predicted and reported sex; (4) genetically identified 347 duplicates (samples with higher call rate were retained); and (5) high rates of heterozygosity (± 4 348 s.d. away from mean within each dataset). Genome sequencing: we applied variant quality score

recalibration (VQSR) to calculate the variant quality score log-odds (VQSLOD) for each variant using GATK v4.4. Variants in the range of VQSLODs corresponding to the remaining 0.5% of the truth set were removed. Furthermore, we kept variants that meet all the following criteria: (1) mean GQ > 30; (2) mean read depth (DP) > 10; and (3) call rate > 0.9. Details on sample QC were available elsewhere²².

354

Ancestry assignment We selected a set of ~14,000 high-quality common variants that were shared between our subjects and 1KGP subjects for ancestry assignment. Using this set of variants, we created four principal components from the 1KGP subjects and projected our subjects to these components. We then used Random Forest to classify samples into broad genetic ancestry groups (EUR, AFR, SAS, EAS, admixed), with 1KGP as the training dataset. We only retained the EUR samples for this study, as the number of cases for other ancestry groups was too small for robust association analysis.

362

363 Association analysis. Broad Institute: Association analyses were performed using a logistic 364 mixed model implemented in REGENIE v.2.2.4. A set of high-confidence variants (>1% MAF, 365 99% call rate, LD-pruned) was used for polygenic effect parameter estimation (Step 1). To 366 control for case-control imbalance, Firth correction was applied to association tests with p-value 367 < 0.05. To control for residual population structure, we calculated five PCs using a set of well-368 genotyped common SNPs, excluding regions with known long-range LD. We included a binary 369 variable representing the sample sequencing platform to control for the sequencing heterogeneity (Twist or Nextera). These variables were used as covariates in both single-variant and burden 370 371 tests, along with sex and the polygenic effect parameter calculated in Step 1. Sanger Institute: 372 A similar pipeline has been applied at the Sanger Institute. We used REGENIE v3.1.2 to 373 calculate the leave-one-chromosome-out (LOCO) score (Step 1) based on a set of high-quality variants (MAF > 1%, HWE P > 1e-15, LD-pruned with R2=0.9, and not from long-range LD 374 375 regions). We then performed logistic regression using the LOCO score, sex, and four PCs as covariates in the model (Step 2). PCs were calculated based on variants with MAF > 0.1% and 376 HWE P > 1e-15; variants from long-range LD regions or known IBD regions were excluded. 377 We applied the fast Firth correction (flags: "--firth --approx") to association tests with p-values < 378 379 0.05 to correct for effect size estimation bias caused by case-control imbalance.

380

Meta-analysis. We used METAL³¹ with an IVW fixed-effect model to meta-analyze

- 382 the association statistics across different studies.
- 383

Clinical variant Annotation. Cystic Fibrosis variant annotation was downloaded from the
Variant List History tab on CFTR2.org on April 23rd, 2024. Each variant was mapped to variant
ID in GRCh38 by its cDNA name.

388 Variant annotation for molecular effect. Non-synonymous variants were classified using 389 Ensembl Variant Effect Predictor (VEP v.95.0 in Broad institute and VEP v.110.1 in Sanger institute)³² as one of the following most severe consequences: "frameshift_variant", 390 391 "stop gained", "splice acceptor variant", "splice_donor_variant", "inframe deletion", 392 "inframe_insertion", "stop_lost", "start_lost", "missense_variant". Predicted loss-of-function 393 variants are defined as variants annotated by VEP as one of the following mutation types: 394 "frameshift_variant", "stop_gained", "splice_acceptor_variant", "splice_donor_variant".

395

396 Variant Annotation using AlphaMissense. AlphaMissense (AM) predictions for all single
397 amino acid substitutions in the human proteome data were downloaded and subsetted to 698
398 CFTR missense variants available in the Broad discovery dataset.

399

400 DATA AVAILABILITY

401 Genome Reference Consortium Human Build 38 can be accessed at 402 https://www.ncbi.nlm.nih.gov/assembly/. Cystic Fibrosis variant annotation data can be downloaded from the Variant List History tab on CFTR2.org. AlphaMissense pathogenicity 403 404 scores can be downloaded from https://zenodo.org/records/8208688. Sequence data used in this 405 study has been made publicly available in dbGaP Study Accession: phs001642.v2.p1 - Center for 406 Common Disease Genomics [CCDG] - Autoimmune: Inflammatory Bowel Disease (IBD) 407 and Genomes (https://www.ncbi.nlm.nih.gov/projects/gap/cgi-Exomes 408 bin/study.cgi?study_id=phs001642.v2.p1).

409

410 CODE AVAILABILITY

The software and code used are described throughout the Methods and can be found at
https://github.com/mingRYU/CFTR-IBD.

- 413
- 414

415 **Reference**

- 416 1. Welsh, M. J. & Smith, A. E. Molecular mechanisms of CFTR chloride channel dysfunction
- 417 in cystic fibrosis. *Cell* **73**, 1251–1254 (1993).
- 418 2. Anderson, M. P. et al. Demonstration that CFTR is a chloride channel by alteration of its
- 419 anion selectivity. *Science* **253**, 202–205 (1991).
- 420 3. Cheng, S. H. et al. Defective intracellular transport and processing of CFTR is the
- 421 molecular basis of most cystic fibrosis. *Cell* **63**, 827–834 (1990).
- 422 4. Lara-Reyna, S., Holbrook, J., Jarosz-Griffiths, H. H., Peckham, D. & McDermott, M. F.
- 423 Dysregulated signalling pathways in innate immune cells with cystic fibrosis mutations.
- 424 *Cell. Mol. Life Sci.* **77**, 4485–4503 (2020).
- 425 5. Keiser, N. W. *et al.* Defective innate immunity and hyperinflammation in newborn cystic
- 426 fibrosis transmembrane conductance regulator-knockout ferret lungs. *Am. J. Respir. Cell*
- 427 *Mol. Biol.* **52**, 683–694 (2015).
- 428 6. Rottner, M., Kunzelmann, C., Mergey, M., Freyssinet, J.-M. & Martínez, M. C.
- 429 Exaggerated apoptosis and NF-kappaB activation in pancreatic and tracheal cystic fibrosis
- 430 cells. *FASEB J.* **21**, 2939–2948 (2007).
- 431 7. Venkatakrishnan, A. *et al.* Exaggerated activation of nuclear factor-kappaB and altered
- 432 IkappaB-beta processing in cystic fibrosis bronchial epithelial cells. Am. J. Respir. Cell
- 433 *Mol. Biol.* **23**, 396–403 (2000).
- 434 8. Zhang, Y.-L. *et al.* Increased intracellular Cl concentration promotes ongoing inflammation
 435 in airway epithelium. *Mucosal Immunol.* 11, 1149–1157 (2018).
- 436 9. Bruscia, E. M. & Bonfield, T. L. Innate and Adaptive Immunity in Cystic Fibrosis. *Clin.*
- 437 *Chest Med.* **37**, 17–29 (2016).

- 438 10. Simonin-Le Jeune, K. *et al.* Impaired functions of macrophage from cystic fibrosis patients:
- 439 CD11b, TLR-5 decrease and sCD14, inflammatory cytokines increase. *PLoS One* **8**, e75667
- 440 (2013).
- 11. Ralhan, A. *et al.* Current Concepts and Controversies in Innate Immunity of Cystic Fibrosis
- 442 Lung Disease. J. Innate Immun. 8, 531–540 (2016).
- 443 12. Ratner, D. & Mueller, C. Immune responses in cystic fibrosis: are they intrinsically
- 444 defective? Am. J. Respir. Cell Mol. Biol. 46, 715–722 (2012).
- 13. Aldallal, N. *et al.* Inflammatory response in airway epithelial cells isolated from patients
- 446 with cystic fibrosis. Am. J. Respir. Crit. Care Med. 166, 1248–1256 (2002).
- 447 14. Becker, M. N. *et al.* Cytokine secretion by cystic fibrosis airway epithelial cells. *Am. J.*448 *Respir. Crit. Care Med.* 169, 645–653 (2004).
- 449 15. Bolton, C. *et al.* An Integrated Taxonomy for Monogenic Inflammatory Bowel Disease.
 450 *Gastroenterology* 162, 859–876 (2022).
- 451 16. Bresso, F. et al. Potential role for the common cystic fibrosis DeltaF508 mutation in
- 452 Crohn's disease. *Inflamm. Bowel Dis.* **13**, 531–536 (2007).
- 453 17. Bahmanyar, S., Ekbom, A., Askling, J., Johannesson, M. & Montgomery, S. M. Cystic
- 454 fibrosis gene mutations and gastrointestinal diseases. J. Cyst. Fibros. 9, 288–291 (2010).
- 18. Shakhnovich, V. *et al.* P-199 pathogenic CFTR mutation in crohn □s disease in the absence
- 456 of other CFTR-related manifestations. *Inflamm. Bowel Dis.* **22**, S69 (2016).
- 457 19. Bresso, F. & D'Amato, M. The cystic fibrosis F508del mutation in Crohn's disease. *J. Cyst.*458 *Fibros.* 10, 132 (2011).
- 459 20. Huang, H. *et al.* Fine-mapping inflammatory bowel disease loci to single-variant resolution.
- 460 *Nature* **547**, 173–178 (2017).

- 461 21. Rivas, M. A. et al. Deep resequencing of GWAS loci identifies independent rare variants
- 462 associated with inflammatory bowel disease. *Nat. Genet.* **43**, 1066–1073 (2011).
- 463 22. Sazonovs, A. et al. Large-scale sequencing identifies multiple genes and rare variants
- 464 associated with Crohn's disease susceptibility. *Nat. Genet.* **54**, 1275–1283 (2022).
- 465 23. Liu, Z. *et al.* Genetic architecture of the inflammatory bowel diseases across East Asian and
 466 European ancestries. *Nat. Genet.* 55, 796–806 (2023).
- 467 24. The Clinical and Functional TRanslation of CFTR (CFTR2); available at http://cftr2.org.
- 468 25. Cheng, J. et al. Accurate proteome-wide missense variant effect prediction with
- 469 AlphaMissense. *Science* **381**, eadg7492 (2023).
- 470 26. Ljungdahl, A. et al. AlphaMissense is better correlated with functional assays of missense

471 impact than earlier prediction algorithms. *bioRxiv* (2023) doi:10.1101/2023.10.24.562294.

- 472 27. McDonald, E. F., Oliver, K. E., Schlebach, J. P., Meiler, J. & Plate, L. Benchmarking
- AlphaMissense Pathogenicity Predictions Against Cystic Fibrosis Variants. *bioRxiv* (2023)
 doi:10.1101/2023.10.05.561147.
- 475 28. Laukoetter, M. G., Nava, P. & Nusrat, A. Role of the intestinal barrier in inflammatory
- 476 bowel disease. *World J Gastroenterol* **14**, 401–407 (2008).
- 477 29. Gabriel, S. E., Brigman, K. N., Koller, B. H., Boucher, R. C. & Stutts, M. J. Cystic fibrosis
 478 heterozygote resistance to cholera toxin in the cystic fibrosis mouse model. *Science* 266,
- 479 107–109 (1994).
- 480 30. Pier, G. B. *et al.* Salmonella typhi uses CFTR to enter intestinal epithelial cells. *Nature* 393,
 481 79–82 (1998).
- 482 31. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of
- 483 genomewide association scans. *Bioinformatics* **26**, 2190–2191 (2010).

484 32. McLaren, W. et al. The Ensembl Variant Effect Predictor. Genome Biol. 17, 122 (2016).